OpGen

OpGen Goodwill

Goodwill of OpGen (OPGN) as of Oct 22, 2026.

Goodwill

0.00USD

Last updated:

Goodwill of OpGen is 2022 0.00 USD. Goodwill of OpGen was 2021 7.45 M USD. It decreases by % lower compared to the previous year.

The OpGen Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2015
637,528.00 USD
Jan 1, 2016
600,814.00 USD
Jan 1, 2017
600,814.00 USD
Jan 1, 2018
600,814.00 USD
Jan 1, 2019
600,814.00 USD
Jan 1, 2020
8.02 M USD
Jan 1, 2021
7.45 M USD
Jan 1, 2022
0.00 USD
The OpGen Goodwill history
YEARGoodwillYoY
0.00USD-100.00%
7.45 MUSD-7.12%
8.02 MUSD+1,235.64%
600,814.00USD0.00%
600,814.00USD0.00%
600,814.00USD0.00%
600,814.00USD-5.76%
637,528.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

On Eulerpool you can find the complete historical development of Goodwill OpGen since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen